“We rate SPRO Overweight. As the company advances its pipeline toward commercialization, we expect upward earnings revisions and multiple expansion to levels not reflected in FactSet consensus expectations to drive SPRO’s stock higher. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our $27 12-month price target. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our $27 12-month price target.”,” Cantor Fitzgerald’s analyst commented.
A number of other equities analysts also recently commented on the company. Zacks Investment Research downgraded Spero Therapeutics from a buy rating to a hold rating in a report on Friday, January 18th. Oppenheimer set a $30.00 price target on Spero Therapeutics and gave the company a buy rating in a report on Sunday, January 13th. ValuEngine downgraded Spero Therapeutics from a buy rating to a hold rating in a report on Wednesday, January 2nd. Finally, Bank of America downgraded Spero Therapeutics from a neutral rating to an underperform rating and lowered their price target for the company from $19.00 to $9.00 in a report on Tuesday, October 16th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. Spero Therapeutics has an average rating of Hold and a consensus target price of $20.65.
NASDAQ:SPRO traded down $0.05 during mid-day trading on Monday, reaching $11.75. The stock had a trading volume of 81,313 shares, compared to its average volume of 50,652. Spero Therapeutics has a fifty-two week low of $5.52 and a fifty-two week high of $19.00. The company has a market capitalization of $202.22 million, a P/E ratio of -0.66 and a beta of 2.94.
Institutional investors have recently made changes to their positions in the company. EcoR1 Capital LLC bought a new position in Spero Therapeutics in the third quarter worth $9,383,000. Aquilo Capital Management LLC lifted its holdings in shares of Spero Therapeutics by 91.9% during the third quarter. Aquilo Capital Management LLC now owns 799,691 shares of the company’s stock valued at $8,405,000 after acquiring an additional 383,000 shares during the period. Artal Group S.A. lifted its holdings in shares of Spero Therapeutics by 71.4% during the third quarter. Artal Group S.A. now owns 600,000 shares of the company’s stock valued at $6,306,000 after acquiring an additional 250,000 shares during the period. AWM Investment Company Inc. lifted its holdings in shares of Spero Therapeutics by 284.8% during the third quarter. AWM Investment Company Inc. now owns 540,474 shares of the company’s stock valued at $5,680,000 after acquiring an additional 400,000 shares during the period. Finally, Vanguard Group Inc lifted its holdings in shares of Spero Therapeutics by 264.8% during the third quarter. Vanguard Group Inc now owns 455,416 shares of the company’s stock valued at $4,787,000 after acquiring an additional 330,580 shares during the period. Institutional investors and hedge funds own 57.53% of the company’s stock.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.
Further Reading: Limitations of the P/E Growth ratio
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.